Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States

BACKGROUND: Brexanolone injection (BRX) was approved by the FDA in 2019 for the treatment of adult patients with postpartum depression (PPD), but its cost-effectiveness has not yet been evaluated. OBJECTIVE: To estimate the cost-effectiveness of BRX compared with treatment with selective serotonin r...

Descripción completa

Detalles Bibliográficos
Autores principales: Eldar-Lissai, Adi, Cohen, Joshua T., Meltzer-Brody, Samantha, Gerbasi, Margaret E., Chertavian, Elizabeth, Hodgkins, Paul, Bond, Julia C., Johnson, Scott J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391201/
https://www.ncbi.nlm.nih.gov/pubmed/32191592
http://dx.doi.org/10.18553/jmcp.2020.19306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391201/
https://www.ncbi.nlm.nih.gov/pubmed/32191592
http://dx.doi.org/10.18553/jmcp.2020.19306

Ejemplares similares